Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Michael Poch"'
Autor:
Amy Hall, Shari Pilon-Thomas, Matthew Beatty, Michael Poch, Jamie Blauvelt, Sarah Bazargan, Katarzyna A Rejniak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a0e68f5ec0694c36833e63f2ddda6eb1
Autor:
Prithvi B. Murthy, Shreyas Naidu, Facundo Davaro, Philippe E. Spiess, Logan Zemp, Michael Poch, Rohit Jain, Aram Vosoughi, G. Daniel Grass, Alice Yu, Wade J. Sexton, Scott M. Gilbert, Roger Li
Publikováno v:
Current Oncology, Vol 30, Iss 3, Pp 3223-3231 (2023)
Introduction and Objective: Muscle invasive bladder cancer with extravesical extension is an aggressive disease entity that requires multimodal therapy. The benefits of adjuvant chemotherapy (AC) in patients with a positive soft-tissue surgical margi
Externí odkaz:
https://doaj.org/article/25aa6f4838164223bb8063a3424aa1fa
Autor:
Sarah Bazargan, Brittany Bunch, Awino Maureiq E. Ojwang‘, Jamie Blauvelt, Annick Landin, Johannes Ali, Dominique Abrahams, Cheryl Cox, Amy M. Hall, Matthew S. Beatty, Michael Poch, Katarzyna A. Rejniak, Shari Pilon-Thomas
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundNew therapeutics in development for bladder cancer need to address the recalcitrant nature of the disease. Intravesical adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) can potentially induce durable responses in bladde
Externí odkaz:
https://doaj.org/article/6a8fb4e5eb7f4745af9760012bdd39fc
Autor:
Angelina K. C. Fink, Amanda C. DeRenzis, Shivanshu Awasthi, Nawreen Jahan, Peter A. S. Johnstone, Julio Pow‐Sang, Javier Torres‐Roca, Daniel Grass, Daniel Fernandez, Arash Naghavi, Susan Tan, Brandon Manley, Roger Li, Michael Poch, Alice Yu, Nikki Little, Eppie Bass, Cesar E. Ercole, Evangelia Katsoulakis, Ryan Burri, Riley Smith, Nathanael B. Stanley, Susan T. Vadaparampil, Kosj Yamoah
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1869-1877 (2023)
Abstract Participation in cancer research trials by minority populations is imperative in reducing disparities in clinical outcomes. Even with increased awareness of the importance of minority patient inclusion in clinical research to improve cancer
Externí odkaz:
https://doaj.org/article/34ce927cf9124a16ad2aa168603939d3
Autor:
Nagi B. Kumar, Saira Bahl, Jasreman Dhillon, Michael Poch, Brandon Manley, Roger Li, Michael Schell, Julio Powsang
Publikováno v:
Cancers, Vol 15, Iss 4, p 1257 (2023)
Clinical trials play a critical role in evidence-based medicine, when rigorous scientific methodology is utilized to discover and test the effectiveness and safety of new drugs to prevent or cure diseases, including cancer. Participation in clinical
Externí odkaz:
https://doaj.org/article/e2f15f4187bb48df95ee68b3f3003192
Autor:
Nainesh Parikh, MD, MBA, Edward Keshishian, MD, Ayushman Sharma, MD, Monica Roca, MD, Brandon Manley, MD, Michael Poch, MD, G. Daniel Grass, MD, PhD, Javier Torres-Roca, MD, David Boulware, MS, MBA, Peter Johnstone, MD, Michael Montejo, MD, Johnna Smith, ARNP, Julio Pow-Sang, MD, Kosj Yamoah, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 5, Iss 5, Pp 905-909 (2020)
Purpose: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) represents 90% of all chronic prostatitis cases and may occur after radiation therapy (RT) for localized prostate cancer. Medical therapy is effective in approximately 50% of cases,
Externí odkaz:
https://doaj.org/article/650deeb5524d49b4baaefd77e80d76e5
Autor:
Nagi B. Kumar, Stephanie Hogue, Julio Pow-Sang, Michael Poch, Brandon J. Manley, Roger Li, Jasreman Dhillon, Alice Yu, Doratha A. Byrd
Publikováno v:
Cancers, Vol 14, Iss 16, p 3988 (2022)
Accumulating evidence supports green tea catechins (GTCs) in chemoprevention for prostate cancer (PCa), a leading cause of cancer morbidity and mortality among men. GTCs include (−)-epigallocatechin-3-gallate, which may modulate the molecular pathw
Externí odkaz:
https://doaj.org/article/380335a8d765466386317160e55c02f1
Autor:
Rohit Jain, Shari Pilon-Thomas, Anders Berglund, Roger Li, Jose Conejo-Garcia, James Mule, Jingsong Zhang, Ryan Putney, Logan Zemp, Jasreman Dhillon, Youngchul Kim, Daniel Grass, Michael Poch, Julio Pow-Sang, Wade Sexton, Scott Gilbert, Colin Dinney
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/d9849c44bbcb4598893709d8de59cd6f
Autor:
Jennifer Morse, Shari Pilon-Thomas, Patrick Innamarato, Sarah Asby, Matthew Beatty, Michael Poch, Brittany L Bunch, Jamie Blauvelt, Ahmet M Aydin, Ali Hajiran
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background The therapeutic armamentarium of bladder cancer has been recently enriched with the introduction of new therapies including immune checkpoint inhibitors, receptor tyrosine kinase inhibitors and antibody drug conjugates, however treatment r
Externí odkaz:
https://doaj.org/article/50a9c72270694fdd84eb11ba7aa1699d
Autor:
Michael Poch, MacLean Hall, Autumn Joerger, Krithika Kodumudi, Matthew Beatty, Pasquale P. Innamarato, Brittany L. Bunch, Mayer N. Fishman, Jingsong Zhang, Wade J. Sexton, Julio M. Pow-Sang, Scott M. Gilbert, Philippe E. Spiess, Jasreman Dhillon, Linda Kelley, John Mullinax, Amod A Sarnaik, Shari Pilon-Thomas
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
Advanced bladder cancer patients have limited therapeutic options resulting in a median overall survival (OS) between 12 and 15 months. Adoptive cell therapy (ACT) using tumor infiltrating lymphocytes (TIL) has been used successfully in treating pati
Externí odkaz:
https://doaj.org/article/cafde76b1d93456999f2cb339a9c7b7c